About This Page
This is a clinician-written, evidence-based summary aligned to the USMLE Step 2 CK Content Outline. It is intended for medical students preparing for USMLE Step 2 CK. Management reflects current ACC/AHA, USPSTF, and APA guidelines. Always cross-reference with UpToDate, institutional protocols, and clinical judgment.
The Bottom Line
- Primary open-angle glaucoma is chronic, usually bilateral, and often asymptomatic until advanced peripheral visual field loss develops
- Classic findings: increased cup-to-disc ratio, optic nerve rim thinning, arcuate scotoma/nasal step, and open angle on gonioscopy
- Elevated intraocular pressure is the major modifiable risk factor, but normal-tension glaucoma can occur
- First-line treatment: topical prostaglandin analog such as latanoprost, travoprost, or bimatoprost
- USMLE pearl: painless tunnel vision + optic disc cupping = open-angle glaucoma; painful red eye with halos/vomiting = angle closure
Overview
Primary open-angle glaucoma (POAG) is a chronic progressive optic neuropathy characterized by retinal ganglion cell loss, optic nerve head remodeling, and corresponding visual field defects. The anterior chamber angle remains anatomically open, distinguishing it from angle-closure disease. Elevated intraocular pressure (IOP) is common and clinically important, but the diagnosis is not based on IOP alone: optic nerve appearance and reproducible visual field or retinal nerve fiber layer changes define disease. Vision loss is irreversible, so the clinical goal is early detection, IOP reduction, and slowing progression.
Epidemiology
Open-angle glaucoma is the most common glaucoma subtype in the United States and a leading cause of irreversible blindness worldwide. Prevalence rises sharply with age. Risk factors include age >60, African American or Hispanic ancestry, first-degree family history, elevated IOP, thin central corneal thickness, high myopia, diabetes mellitus, hypertension, obstructive sleep apnea, and chronic corticosteroid exposure. African American patients have earlier onset and higher risk of severe visual loss.
Clinical Features
Symptoms
Usually asymptomatic for years; often detected during routine eye examination
Gradual peripheral visual field loss, classically progressing to tunnel vision
Difficulty with night driving, stairs, or bumping into objects late in disease
No acute ocular pain, nausea, or halos around lights — those suggest angle closure instead
Sudden vision loss is atypical and should trigger evaluation for retinal detachment, vascular occlusion, optic neuritis, or stroke
Signs
Increased cup-to-disc ratio, asymmetric cupping, vertical rim thinning, or optic disc hemorrhage
Open anterior chamber angle on gonioscopy
Elevated IOP often >21 mmHg, but may be normal in normal-tension glaucoma
Visual field defects: nasal step, arcuate scotoma, paracentral scotoma, or advanced tunnel vision
Relative afferent pupillary defect if asymmetric advanced disease
Corneal edema, fixed mid-dilated pupil, and severe eye pain are NOT typical and suggest acute angle closure
Investigations
First-line
TonometryMeasures intraocular pressure. Normal is roughly 10-21 mmHg, but glaucoma can occur at normal IOP and ocular hypertension can occur without glaucoma
Dilated optic nerve examinationAssess cup-to-disc ratio, neuroretinal rim thinning, notching, asymmetry, and disc hemorrhage
Automated visual field testingIdentifies functional loss: nasal step, arcuate scotoma, paracentral defects, or generalized constriction
GonioscopyConfirms open angle and excludes angle-closure or secondary angle pathology
Second-line
Optical coherence tomography (OCT)Measures retinal nerve fiber layer and ganglion cell complex thinning; useful for early disease and monitoring progression
PachymetryCentral corneal thickness affects IOP interpretation. Thin cornea is also an independent progression risk factor
Optic disc photographyBaseline structural documentation for progression monitoring
Specialist
Serial progression analysisLongitudinal OCT, disc photos, IOP trend, and repeat visual fields guide target IOP and escalation
Evaluation for secondary glaucomaConsider pigment dispersion, pseudoexfoliation, uveitis, trauma, neovascular glaucoma, or steroid-induced glaucoma when findings are atypical
1
Initial approach
- Refer to ophthalmology for baseline gonioscopy, optic nerve assessment, visual field testing, and OCT
- Set an individualized target IOP based on baseline IOP, optic nerve damage, visual field loss, age, life expectancy, and progression risk
- Educate that treatment preserves remaining vision but does not restore lost visual field
- Review adherence carefully — topical glaucoma therapy fails commonly because the patient is asymptomatic
2
First-line IOP-lowering therapy
- Topical prostaglandin analog once nightly: latanoprost, travoprost, bimatoprost, or tafluprost
- Expected IOP reduction ~25-33%; major adverse effects: conjunctival hyperemia, eyelash growth, iris darkening, periocular skin darkening
- Alternative/adjuncts: topical beta-blocker (timolol), alpha-2 agonist (brimonidine), topical carbonic anhydrase inhibitor (dorzolamide, brinzolamide), rho kinase inhibitor (netarsudil)
- Avoid topical beta-blockers in asthma/COPD with bronchospasm, severe bradycardia, high-grade AV block, or decompensated heart failure
3
Laser and procedural treatment
- Selective laser trabeculoplasty (SLT) can be first-line or adjunctive therapy, especially when adherence is poor
- Trabeculectomy or tube shunt for advanced disease, uncontrolled IOP, or progression despite maximal tolerated therapy
- Minimally invasive glaucoma surgery may be combined with cataract surgery in selected mild-to-moderate cases
4
Follow-up and prevention
- Monitor IOP, optic nerve, OCT, and visual fields at intervals based on severity and stability
- Screen high-risk groups with comprehensive eye examination; USPSTF finds insufficient evidence for population screening by primary care alone
- Treat systemic risk factors and avoid unnecessary corticosteroids when possible
Complications
- Irreversible visual field loss: Peripheral loss progresses silently before central vision is affected
- Legal blindness: Advanced bilateral disease can cause severe functional impairment
- Medication adverse effects: Prostaglandin-associated iris pigmentation; beta-blocker bronchospasm/bradycardia
- Postoperative complications: Hypotony, bleb leak, infection, or cataract progression after filtering surgery
- Quality-of-life decline: Falls, driving difficulty, reduced mobility, and loss of independence
USMLE Step 2 CK Exam Tips
- 1Painless progressive peripheral vision loss + increased cup-to-disc ratio = primary open-angle glaucoma
- 2Best initial diagnostic test in a screening-style vignette is tonometry plus optic nerve examination; formal diagnosis requires visual field/OCT correlation
- 3First-line medication is a prostaglandin analog such as latanoprost, not pilocarpine
- 4Topical timolol can cause bronchospasm and bradycardia — avoid in asthma/COPD or AV block
- 5Normal IOP does not exclude glaucoma; optic nerve damage and field loss matter
- 6Open-angle glaucoma is chronic and painless; angle-closure glaucoma is acute, painful, red, and associated with halos and vomiting
- 7African American patient + family history + asymptomatic cupping = high-yield POAG risk pattern
- 8Vision loss from glaucoma is irreversible — treatment prevents progression rather than restoring vision
practicetest your knowledge on open-angle glaucomaApply what you've learnt with USMLE Step 2 CK-style questions from the iatroX Q-Bank — ophthalmology and beyond.
open q-bank